Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) will present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021, at 2:00 p.m. ET in Jupiter, Florida. The company recently received regulatory clearance from an Australian Human Research Ethics Committee to start a Phase 1 trial for its orally administered CC-42344 drug targeting influenza A. CFO James Martin expressed enthusiasm for discussing the company's COVID-19 antiviral programs during the presentation. A live and archived webcast will be available on the company's website.

BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces that management will present at the Dawson James 2021 Small Cap Growth Conference on Thursday, October 21, 2021 at 2:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.

“We are excited about recently receiving regulatory clearance from an Australian Human Research Ethics Committee (HREC) to initiate our Phase 1 trial in healthy volunteers with orally administered CC-42344 as a treatment for pandemic and seasonal influenza A, which remains a major global health concern,” said James Martin, CFO and interim co-CEO of Cocrystal. “We also look forward to discussing milestones with our COVID-19 antiviral programs during the presentation at this conference.”

A webcast of the presentation will be available live and archived on the IR Calendar of the company website.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, hepatitis C virus and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

# # #

FAQ

What is the date of Cocrystal Pharma's presentation at the Dawson James conference?

Cocrystal Pharma will present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021.

What time will Cocrystal Pharma's presentation take place?

Cocrystal Pharma's presentation is scheduled for 2:00 p.m. Eastern Time.

What drug is Cocrystal Pharma initiating a Phase 1 trial for?

Cocrystal Pharma is initiating a Phase 1 trial for its orally administered drug CC-42344, targeting influenza A.

What recent regulatory approval did Cocrystal Pharma receive?

Cocrystal Pharma received regulatory clearance from an Australian Human Research Ethics Committee to initiate its Phase 1 trial.

Where is the Dawson James 2021 Small Cap Growth Conference being held?

The conference is being held at the Wyndham Grand Hotel in Jupiter, Florida.